Primary source: Elligint Health via EIN Presswire, November 12, 2026, 15:05 GMT
On November 12, 2026, Elligint Health said it acquired Laguna Health. Elligint sells care management and utilization management technology to health plans. Laguna's AI prepares the care manager, sits on the member call, and writes the note after. If you run provider revenue cycle, that is the payer side of the conversation your utilization reviews already sit in. The release does not say the software approves, denies, or touches a claim.
Elligint's About in the same release says the company manages more than 13 million lives across all 50 states. Calcalist estimates the deal at tens of millions of dollars. That estimate is the reporter's. It is not a disclosed price.
| Element | What November 12 published |
|---|---|
| Buyer | Elligint Health, datelined Edison, N.J. The release calls it “a provider of care management and utilization management technology for health plans.” The About calls it a performance engine for health plans and risk-bearing organizations: Helios for care management and utilization management, Advanced Analytics, the Helios Partner Ecosystem, and now Laguna. |
| Scale | The About says “more than 13 million lives managed across all 50 states.” HIT Consultant, Fred Pennic, the same day, assigns that figure to Helios. The release assigns it to Elligint Health. |
| Target | Laguna Health, “a conversational AI company built for health plan, care management and other front-line healthcare staff.” The About says it was founded in 2020 by Yoni Shtein and Yael Peled Adam, with offices in Edison, N.J., and Tel Aviv. HIT Consultant reports the same founding line. |
| Status | The release says Elligint “has acquired” Laguna. Laguna becomes a wholly owned subsidiary and keeps its name, products, and website. Yoni Shtein, Laguna's co-founder, stays CEO. Customers of both companies keep their current teams. |
| Price | Not in the release. No revenue, no customer names, and no Elligint owner or backer. Calcalist, Meir Orbach, November 12, says the value was not disclosed and estimates “tens of millions of dollars.” |
| What Laguna does | Laguna Companion prepares care managers before calls, supports them during member conversations, and automates post-call documentation. Laguna Insight reviews every call against a plan's own standards instead of a small sample, and was named one of TIME's Best Inventions of 2024. LISA is an agentic AI assistant for autonomous member outreach, assessment, and warm handoff to care teams. |
| How it is sold | Plans can use Laguna on its own, inside the care-management systems they already run, with no integration required to go live, or together with Helios. Elligint plans to connect Laguna with Helios over time, starting with Companion, and will keep selling each product independently. |
| The proof, as claimed | The release says Laguna documents member conversations with 99% clinical content accuracy, that a multi-state health plan cut documentation time by 66% in a published customer case study, and that the approach is supported by a peer-reviewed randomized controlled trial in the Journal of Healthcare Management. Those are company claims. The release does not name the plan, the paper, the sample, or the trial result. |
This is not a first meeting. Elligint's newsroom dated a commercial partnership October 6, 2026: Helios clients would get Laguna's tools for care teams. Thirty-seven days later the same newsroom posted the acquisition. The October item calls Laguna a conversational AI company for payer case management. The November 12 release says care management. Neither item prints a price.
The release's About Laguna names institutional investors: Pitango HealthTech, LionBird, A-Squared Ventures, HC9 Ventures, and SemperVirens. That list is not a valuation. Calcalist reports Laguna has raised approximately $30 million since founding, employs approximately 20 people in Tel Aviv, and that Elligint plans to double that Israeli workforce, including developers, AI engineers, and U.S.-market sales roles. Those three figures are Calcalist's. They are not in the release, and this article does not use Calcalist's investor names, which do not match the About.
Read the products as a sequence on one call. Companion is the co-pilot: context before the dial, support while the member is on the line, documentation after. Insight is the audit of that call, every one of them, scored to the plan's own standards rather than a sample a supervisor had time to hear. LISA is the agent that can start the outreach, run an assessment, and hand the member to a person. The release's line for the combination is that Laguna turns every member conversation into documentation, quality review, and insight, measured against each plan's own clinical standards.
The opening of the release places that work “inside Helios, where care and utilization management teams already do their work.” A later paragraph says a plan can go live inside the care-management system it already runs, with no integration required, or use Helios. Both sentences are in the wire. The connection to Helios is a plan, starting with Companion, not a finished integration. Each product keeps its own sale.
“Health plans want AI that helps care teams in their daily work, and they want proof that it's accurate and safe,” said Chris Caramanico, CEO of Elligint Health. “Laguna has that proof today. It's a safe, low-risk, high-return use of AI, proven with health plans. It works inside the systems plans already use, and each plan stays in full control, with Laguna configured to its own workflows and protocols. Helios runs the work. Laguna makes every conversation count. Together, we can bring AI into care management faster than either company could alone.”
“Our customers chose Laguna because it gives care managers time back with members and gives leaders a clear view of every conversation,” said Yoni Shtein. “Elligint shares our belief that AI should support care managers, not replace them. With Elligint Health's reach across health plans, we can bring Laguna to many more care teams, and our customers keep the product, team and brand they know.”
The wire uses “has acquired.” It does not print a price, a revenue figure, a customer, or who owns Elligint. Calcalist's “tens of millions” stays an estimate. The 99 percent accuracy and the 66 percent documentation cut are the company's, tied to an unnamed multi-state plan and an unnamed Journal of Healthcare Management trial. The release does not mention a claim, a denial, or a prior authorization decision. Do not treat the call note as an auth determination.
This is RevCycleAI's read. Utilization management is the payer half of prior authorization. Care-management outreach is the call that sits around it: the nurse, the assessment, the note a plan later uses when it asks whether the care was necessary. Provider revenue cycle does not run that call. It receives the authorization, the denial, and the record request. Laguna, on the words of this release, is the documentation and the quality review of the payer's side of that conversation. Caramanico's line is the product split. Helios runs the work. Laguna makes every conversation count.
The distribution is the part an operator can actually use. A plan that is not an Elligint customer can buy Laguna inside the care-management system it already has. A Helios customer can add it. Elligint says it will connect the two over time and will keep selling them separately. That is consolidation of the vendor, not a forced rip-and-replace. Shtein says customers keep the product, the team, and the brand. The release says they keep their current teams. It does not say the note lands in a claim, an EHR, or an authorization file.
Elligint's Laguna page, separate from the wire, lists authorizations, reviews, and appeals under what Helios runs, and it says a plan does not need Helios to use Laguna. People, the page says, make every clinical decision. That page is product marketing. It is not a statement that Laguna decides an auth. The acquisition release still does not say so.
The adjacent Elligint item is easy to mash into this one, and it should not be. On November 3 the newsroom said Helios adopted AWS HealthLake as its FHIR store and that the work supports CMS-0057-F electronic prior authorization. That is a different announcement. Read it next to this deal and keep the products apart: Helios is being pointed at the prior-authorization API rule, and Laguna is the AI on the member call. The November 12 release does not say Companion writes the auth.
The provider side of that workflow has been moving on its own calendar. On September 16 R1 launched Phare UM to put payer risk in front of the provider before the bill. Today R1 said Phare UM is one of four Phare OS modules on sale. ONC and CMS opened a voluntary electronic prior authorization test the same day, and passing it is not compliance. On November 10 Google Cloud's Gemini for healthcare connected eligibility and prior auth work to Waystar, Optum, TriZetto, and Infinitus, and it does not submit the claim. AI now sits on the plan's care-management call and on the provider's UM workflow. None of those announcements says the software issues the denial.
Elligint now owns the AI on the health plan's care-management call, and the price was not disclosed. The release documents the conversation against the plan's own standards. It does not decide a prior authorization. Calcalist's “tens of millions” is an estimate. The 13 million lives are Elligint's About.
Watch the note, not a denial rate this release did not print. If Laguna is configured to your payer's protocols, the next utilization review may arrive with a cleaner call record than the sample a supervisor used to pull. Ask which system the note lives in, whether Companion is running standalone or on Helios, and whether that file is what the plan cites when it questions medical necessity. The price is still blank. So is the name of the plan in the 66 percent case study. So is any sentence that says this AI approves or denies.
Who bought the care-management call, what the release actually priced, and what it refused to say about a denial.
Sources: EIN Presswire, “Elligint Health Acquires Laguna Health, Adding Conversational AI for Health Plan Care Management,” Elligint Health, November 12, 2026, 15:05 GMT, Edison, N.J. (page opened); the same announcement on Elligint Health's newsroom (page opened), which also lists the October 6, 2026 commercial partnership and the November 3, 2026 AWS HealthLake / CMS-0057-F item; Elligint's Laguna Health page (page opened); HIT Consultant, Fred Pennic, November 12, 2026 (page opened); Calcalist / CTech, Meir Orbach, November 12, 2026 (page opened). Quotes from Chris Caramanico and Yoni Shtein are verbatim from the EIN Presswire release. HIT Consultant's rendering of the Caramanico quote drops words and is not used. Calcalist's quotations are not used. The acquisition, the wholly owned subsidiary, the retained name, products, and website, Shtein remaining CEO, the three products, the 99 percent accuracy, the 66 percent documentation cut, the Journal of Healthcare Management trial, the standalone-or-Helios distribution, the “more than 13 million lives” sentence, the 2020 founding, the Edison and Tel Aviv offices, and the named Laguna investors are the release's. The October 6 partnership and the November 3 HealthLake sentence are the newsroom's. The authorizations, reviews, and appeals line is the Laguna product page's. The “tens of millions” estimate, the approximately $30 million raised, the approximately 20 Tel Aviv employees, and the plan to double the Israeli workforce are Calcalist's, and the estimate is labeled as an estimate. No price, revenue, or customer name was disclosed, and none is estimated here. There is no prior RevCycleAI article on this deal.